Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Passage Bio, Inc. PASG

Healthcare — Biotechnology
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years ,
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.21
Total sells
0.11
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — 1 — — —
Sell — — — 2 — — — — — — — —
Insider Ownership
7.45%

Capital & Financial Ratios

Market Cap
16.22
Revenue
—
Net Income
(36.11)
Free Cash Flow
(33.48)
Net Debt
(24.15)
Current Ratio
1.22
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
0.00
P/B ratio
3.42
Past 5Y EPS Growth
(1.48%)
This Y EPS Growth
31.85%
Next Y EPS Growth
(4.29%)
Next 5Y EPS Growth
14.82%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 114.29 76.76 46.30 24.16
Receivables — — — —
Inventory — — — —
Other 2.74 1.22 0.83 0.25
117.96 78.82 47.76 25.18
2023 2024 2025 Q'26
Payables 1.30 0.74 1.11 0.90
ST’ Debt — — — —
Other — 8.23 13.75 16.25
16.34 19.36 23.08 20.72
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Year
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (12.99) (9.18) — —
—
’25 (13.85) (6.33) (4.85) (6.48)
(31.51)
’24 (18.93) (13.14) (7.45) (8.44)
(47.96)
’23 (22.45) (17.14) (19.16) (19.52)
(78.26)
’22 (44.71) (26.08) (23.39) (24.02)
(118.21)
’21 (30.72) (24.33) (41.06) (30.77)
(126.88)
’20 (21.85) (11.71) (17.53) (29.42)
(80.52)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (12.97) (9.18) — —
—
’25 (13.26) (5.74) (4.85) (6.48)
(30.34)
’24 (18.93) (13.14) (7.47) (8.46)
(47.99)
’23 (22.47) (17.24) (19.17) (19.53)
(78.41)
’22 (46.94) (26.91) (25.14) (24.49)
(123.48)
’21 (32.02) (29.84) (52.57) (38.09)
(152.52)
’20 (21.95) (11.81) (17.68) (30.73)
(82.17)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (2.36) (2.44) — —
—
’25 (5.00) (2.96) (2.44) (4.08)
(14.35)
’24 (6.00) (5.20) (6.20) (4.00)
(21.40)
’23 (12.60) (8.80) (9.80) (6.00)
(37.20)
’22 (15.80) (14.60) (9.80) (10.00)
(50.00)
’21 (15.20) (18.00) (17.40) (19.00)
(69.60)
’20 (20.00) (12.00) (12.60) (17.00)
(58.20)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

2.3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 20.80 11.50 9.02 5.12 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 131.00 38.40 35.80 20.20 — — —
High Price
— — — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 85 58 60 24 — — —
Employees
— — — ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 — — —
Revenue/Emp
— — — — — — — — — — ‡‡‡‡‡ ‡‡‡‡‡ —
Revenue
— — — ‡‡‡ ‡‡‡ ‡‡‡ 0.00% — — — — — —
Gross Margin
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (136.12) (102.06) (64.77) (45.52) — — —
EBT
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (136.12) (102.06) (64.77) (45.52) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.45 1.69 1.55 0.86 — — —
Depreciation
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Revenue/Sh
— — ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (50.00) (37.20) (21.40) (14.35) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (43.44) (28.59) (15.58) (9.93) — — —
Cash Flow/Sh
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.94) (0.05) (0.01) 0.37 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (45.37) (28.65) (15.59) (9.56) — — —
Free CF/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 73.99 40.66 19.90 5.91 — — —
Book Value/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.72 2.74 3.08 3.17 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — — — — — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— — — — — — — — — — ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — — — — — — — ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — — — — — — — ‡‡‡‡ ‡‡‡‡ —
EV/Sales
— — — — — — — — — — — — —
EV/FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (118.21) (78.26) (47.96) (31.51) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.27) (0.15) (0.03) 1.17 ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (123.48) (78.41) (47.99) (30.34) — — —
FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 178.69 101.62 59.45 24.68 — — —
Working Cap'
— — — — — — 27.11 — — — — — —
Total Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (162.50) (114.29) (76.76) (46.30) — — —
Net Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 201.37 111.28 61.26 18.76 — — —
Sh' Equity
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (45.48%) (51.80%) (51.21%) (55.28%) — — —
ROA
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ (222.57%) 0.00% 0.00% 0.00% — — —
ROIC
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (52.35%) (65.29%) (75.07%) (113.78%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Passage Bio, Inc. (PASG) exemplifies biotech’s brutal volatility: a 2020 SPAC darling that soared to $764 before plummeting 95% to $35.8 amid exploding losses, trial delays, and a workforce slashed 55% to 60 people. With zero revenue through 2024, net losses improving to -$64.8 million via ruthless cost cuts rather than progress, and book value per share halved to $20.3, the company burns cash at a tightening but still perilous rate—net debt down 76% yet ROE at -75%—leaving a 12-18 month runway in a graveyard of failed gene therapies targeting rare neurological disorders.

Insider moves are mixed: a 10% owner scooped 161,000 shares at $5-7 dips for $958,000, outpacing sell costs, while execs trimmed modestly. Analysts dream big with a 200% mean upside target, betting on $1.7 million 2025 revenue from PBGM-01 or PBFT-01 milestones and EPS gains to -$4.2 by 2027. But this contrarian dissects the red flags—90% Phase 2 failure rates, dilution risks, pipeline stumbles, and macro biotech winter—positioning PASG as a speculative lottery, not an investment, until real catalysts emerge.

Dive into the full analysis for granular financials, peer contrasts, and the high-stakes verdict on whether PASG’s wreckage hides treasure or traps.

Read full commentary →

Passage Bio, Inc. (PASG) Latest News

News by impact score

Fine-tune

25 Jun

4 www.biopharmadive.com, 6:55 AM
Remix will go public via reverse merger with Passage Bio (PASG), the former high-flying biotech now serving as the public vehicle for the transaction. Reverse merger replaces Passage Bio's independent operations and trajectory with a new public entity and ownership structure.

24 Jun

5 GlobeNewswire, 4:05 PM
Passage Bio, Inc. (PASG) and Remix Therapeutics announce merger agreement. Merger agreement with Remix Therapeutics will fundamentally alter Passage Bio operations, strategy and market position.

4 stocktwits.com, 6:47 PM
PASG stock fell 16% in after-hours trading on a selloff whose drivers remain unspecified in the headline. A 16% after-hours drop signals sharp negative investor reaction likely to pressure valuation and future capital access.

21 Apr

4 , 2:20 PM
Wedbush analysts state Passage Bio faces a tougher FDA approval path after shifting its clinical trial design. Tougher FDA scrutiny from trial shift significantly delays Passage Bio's regulatory timeline and investor outlook.

3 , 11:46 AM
Oppenheimer views Passage Bio (PASG) as undervalued despite a recent FDA setback. FDA setback moderately impacts Passage Bio's regulatory path and sentiment, balanced by Oppenheimer's undervaluation call.

20 Apr

4 , 7:00 AM
Passage Bio, Inc. (PASG) reports updated interim data from the upliFT-D trial and provides regulatory and corporate updates. Updated interim clinical trial data combined with regulatory updates represent major milestones that can significantly sway biotech stock performance and strategic outlook.

3 Mar

3 GlobeNewswire, 7:00 AM
Passage Bio, Inc. (PASG) reported fourth quarter and full year 2025 financial results alongside recent business highlights. Financial results and business highlights affect key areas like cash position and pipeline progress, with moderate influence on trajectory.

10 Nov

4 GlobeNewswire, 4:15 PM
Passage Bio, Inc. reported its financial results for the third quarter of 2025, highlighting key business developments and financial metrics. The company continues to advance its gene therapy programs and has made progress in clinical trials. Recent partnerships and collaborations were also noted, indicating a focus on expanding its research capabilities and market presence. Overall, the report reflects the company's ongoing commitment to innovation in genetic medicine. Significant advancements in clinical trials and strategic partnerships could notably enhance the company's market position and investor sentiment.

5 Nov

3 GlobeNewswire, 7:00 AM
Passage Bio, Inc. will present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference, highlighting its advancements in gene therapies for neurological diseases. The presentation is expected to provide insights into the company's pipeline and strategic direction, attracting attention from investors and industry stakeholders. The presentation may influence investor sentiment and provide updates on product development, but its overall impact is expected to be limited.

1 Sep

4 , 9:55 AM
Wall Street analysts project that Passage Bio, Inc. (PASG) could experience a remarkable surge of 731% in its stock price. This optimistic outlook is driven by the company's advancements in gene therapy and potential market opportunities. Investors are encouraged to consider the implications of these projections before making investment decisions. The projected surge in stock price indicates significant potential for major strategic moves and market dynamics that could alter the company's trajectory.

15 Aug

4 Zacks, 9:55 AM
Wall Street analysts project that Passage Bio, Inc. (PASG) could see a remarkable rally of 1415.15%. The article outlines potential trading strategies for investors looking to capitalize on this anticipated growth, emphasizing the company's promising developments and market positioning. Analysts' projections indicate significant potential for growth, which could substantially influence investor sentiment and the company's market trajectory.

12 Aug

4 , 7:00 AM
Passage Bio, Inc. reported its financial results for the second quarter of 2025, highlighting key business developments and financial metrics. The company continues to advance its gene therapy programs and has made progress in clinical trials. Recent collaborations and strategic initiatives were also outlined, indicating a focus on enhancing its product pipeline and market position. Overall, the report reflects the company's ongoing commitment to innovation in the field of genetic medicine. Significant advancements in clinical trials and strategic collaborations could notably enhance the company's market position and investor sentiment.

10 Jul

3 GlobeNewswire, 7:00 AM
Passage Bio, Inc. announced a 1-for-20 reverse stock split effective July 14, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share. The split will reduce the number of outstanding shares from approximately 62.4 million to about 3.1 million, with no change to authorized shares or par value. Stockholders will not need to take action to receive post-split shares, and fractional shares will be rounded up. The reverse stock split was approved by stockholders at the 2025 annual meeting. The reverse stock split is a strategic move to maintain compliance with Nasdaq requirements, which may influence market sentiment and stock performance.

23 Jun

4 GlobeNewswire, 7:00 AM
Passage Bio, Inc. reported updated interim data from its Phase 1/2 upliFT-D clinical trial for PBFT02, a gene therapy targeting frontotemporal dementia (FTD) with granulin mutations. The treatment demonstrated significant increases in cerebrospinal fluid (CSF) progranulin levels and reduced plasma neurofilament levels, indicating potential disease progression benefits. The company plans to amend the trial protocol to include low-dose anticoagulation and modify patient inclusion criteria to enroll those earlier in disease progression. Regulatory feedback on the pivotal trial design is expected in the first half of 2026. The planned protocol amendments and positive interim data could significantly enhance the treatment's efficacy and regulatory approval prospects.

13 May

3 , 7:00 AM
Passage Bio, Inc. reported its financial results for the first quarter of 2025, highlighting key business developments and financial metrics. The company continues to advance its gene therapy programs and is focused on expanding its pipeline. Recent achievements include progress in clinical trials and collaborations aimed at enhancing its research capabilities. The financial results reflect ongoing investments in R&D and operational growth, positioning the company for future advancements in the biotechnology sector. The financial results and business highlights indicate moderate progress in key areas that may influence future performance.

7 Mar

4 Zacks, 12:00 PM
Passage Bio, Inc. (PASG) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive earnings outlook that could boost its stock price. The Zacks rating system, which tracks earnings estimate revisions, suggests that the company's improving business fundamentals may lead to higher stock performance. For the fiscal year ending December 2025, analysts expect the company to earn -$0.69 per share, reflecting a 35.5% change from the previous year, with a 6.1% increase in the Zacks Consensus Estimate over the past three months. The upgrade places Passage Bio in the top 20% of Zacks-covered stocks, signaling potential for market-beating returns. The upgrade reflects significant improvements in earnings estimates, which are likely to influence investor sentiment and stock performance.

4 Mar

4 , 7:00 AM
Passage Bio, Inc. reported its financial results for the fourth quarter and full year of 2024, highlighting key business developments and financial metrics. The company continues to advance its gene therapy programs and has made significant progress in its clinical trials. Management emphasized their commitment to innovation and strategic partnerships to enhance growth and operational efficiency. The results reflect ongoing investments in research and development, positioning the company for future advancements in the biotechnology sector. Significant advancements in clinical trials and strategic partnerships could notably influence the company's future trajectory and market perception.

10 Jan

4 , 7:00 AM
Passage Bio, Inc. announced interim data from its upliFT-D study focused on frontotemporal dementia caused by GRN mutations. The results indicate potential efficacy and safety of the treatment, which is crucial for patients with this genetic condition. Additionally, the company provided updates on its business strategy and ongoing clinical trials, highlighting its commitment to advancing gene therapies for neurodegenerative diseases. The interim data from the upliFT-D study could significantly influence Passage Bio's future product development and market positioning in the gene therapy sector.

29 Dec

4 Simply Wall St., 7:20 AM
Passage Bio had $85m in cash with a cash burn of $59m, giving it 17 months of cash runway. The company reduced its cash burn by 29% year on year, but its cash burn is 146% of its market value, posing a risk of funding distress. The article highlights significant risks to Passage Bio's future and market performance due to high cash burn relative to market value.

30 Nov

4 TipRanks, 6:55 AM
Wedbush assumes coverage of Passage Bio with an Outperform rating and $4 price target, citing potential for PBFT02 in frontotemporal dementia. The Outperform rating and increased price target indicate a significant positive impact on Passage Bio's future and market performance.

29 Nov

3 MT Newswires, 9:00 AM
Wedbush raises price target on Passage Bio to $4 from $3, keeps outperform rating. The increased price target may have a moderately noticeable influence on Passage Bio's future performance.

14 Nov

4 , 7:29 AM
Passage Bio, Inc. (PASG) achieves milestones in gene therapy trials. The achievements in gene therapy trials are likely to have a significant impact on Passage Bio's future and market performance.

13 Nov

3 , 7:00 AM
Passage Bio reports third quarter 2024 financial results and recent business highlights. The financial results and business highlights may moderately influence key areas like financial performance and competitive positioning.

6 Nov

3 , 7:00 AM
Passage Bio, Inc. (PASG) will present at Guggenheim Securities Healthcare Innovation Conference. The presentation at the conference may moderately influence the company's competitive positioning.

24 Oct

4 GlobeNewswire, 7:00 AM
Passage Bio presented preclinical and interim clinical data for PBFT02 in FTD-GRN at the ESGCT 31st Annual Conference. The presentation of positive preclinical and clinical data for PBFT02 could significantly impact Passage Bio's future development and market performance.

23 Sep

3 GlobeNewswire, 7:00 AM
Passage Bio, Inc. will present at Chardan's 8th Annual Genetic Medicines Conference on October 1, 2024. The presentation at the conference may moderately influence key areas such as financial performance and competitive positioning.

19 Sep

3 GuruFocus.com, 1:25 AM
Orbimed Advisors LLC reduced its stake in Passage Bio Inc by 22.63%, selling 2,290,707 shares. The reduction in stake may moderately influence Passage Bio's financial performance and market sentiment.

16 Sep

4 GlobeNewswire, 7:00 AM
Passage Bio to present positive interim data from Cohort 1 patients with FTD-GRN in upliFT-D study at ISFTD2024. Interim data shows robust and sustained increase in CSF progranulin levels, indicating potential significant impact on future treatment of neurodegenerative diseases.

10 Sep

4 GlobeNewswire, 7:52 AM
Passage Bio appoints Tom Kassberg to Board of Directors and Audit Committee, bringing deep biotech executive experience from Ultragenyx and other companies. Tom Kassberg's appointment is expected to have a significant impact on Passage Bio's future strategic planning and corporate development.

30 Aug

3 GlobeNewswire, 7:00 AM
Passage Bio, Inc. will present at H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024. The presentation at the conference may moderately influence investor sentiment and competitive positioning.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us